Floatz logo

Jcar017 (Lisocabtagene Maraleucel)

Recurrent Transformed Chronic Lymphocytic Leukemia

Aseel AlsouqiCell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

56 Active assets in the Recurrent Transformed Chronic Lymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
Obinutuzumab
Christine Ryan
Phase 2BB
Ibrutinib
City of Hope Medical Center
Phase 2BB
Venetoclax
Northwestern University
Phase 2BB
Pirtobrutinib
SWOG Cancer Research Network
Phase 3BB
Cyclophosphamide
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

Jcar017 (Lisocabtagene Maraleucel) is also rated in:

diffuse large B-cell lymphomaDormant
BB
Indicative ·
66 / 100
View asset →
non-Hodgkin lymphomaDormant
BB
Indicative ·
65 / 100
View asset →
primary mediastinal large B-cell lymphomaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →